Frazer Supply CAS 656247-17-5 99% Nintedanib for Antitumor Best Price Nintedanib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Fra3216311
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: off-White or White Powder
• Purity: >99%
• Appearance: off-White or White Powder
• CAS No: 656247-17-5
• Shelf Life: 2 Years
• Test Method: HPLC
• Storage: Store Cool Dry Place
• Quality Requirement: Strictly Quality Control
• Usage: for Antitumor
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

Factory Supply 99% Nintedanib CAS 656247-17-5 for Antitumor

Specification of Analysis

ITEMS	SPECIFICATION	TESTRESULTS
Appearance	Off-white or white powder	Conforms
Identification	HPLC,NMR;LC-MS	Conforms
Related substances	Individual impurity≤0.5%	0.09%
	Total impurities≤1.0%	0.20%
Loss on drying	≤0.5%	0.3%
Residue on ignition	≤0.1%	0.04%
Heavy metals	≤10ppm	Conforms
Assay	≥98.0 %	99.1%

Nintedanib is an anti-angiogenesis anti-cancer agent. Nintedanib is an indolinone-derived drug that inhibits the process of blood vessel formation (angiogenesis)Nintedanib, marketed under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis (IPF) and along with other medications for some types of non-small-cell lung cancer. Common side effects include abdominal pain, vomiting, and diarrhea. It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (R). It was developed by Boehringer Ingelheim. At an assumed cost of 39,300 pounds per year it does not appear to be cost effective for IPF in the United Kingdom.

Application

Nintanib targets platelet-derived growth factor receptors (α and β), fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and the adenosine triphosphate ( ATP) binding sites competitively bind, block the signal pathway of fibrosis process, inhibit the proliferation, metastasis and transformation of fibroblasts, thereby slowing the progression of IPF disease.